Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1858 1
1940 2
1946 1
1947 2
1950 1
1952 1
1953 1
1954 1
1955 1
1957 1
1961 1
1962 1
1963 3
1964 5
1965 6
1966 2
1967 5
1968 3
1969 1
1970 3
1972 5
1973 4
1974 6
1975 5
1976 9
1977 9
1978 10
1979 7
1980 9
1981 10
1982 7
1983 9
1984 11
1985 16
1986 19
1987 22
1988 29
1989 20
1990 18
1991 26
1992 17
1993 13
1994 17
1995 20
1996 19
1997 25
1998 15
1999 23
2000 32
2001 29
2002 33
2003 48
2004 31
2005 44
2006 48
2007 58
2008 60
2009 74
2010 72
2011 88
2012 97
2013 111
2014 112
2015 110
2016 127
2017 116
2018 107
2019 109
2020 136
2021 181
2022 183
2023 168
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

2,457 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. Among authors: gill se. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects.
Jain S, Rick JW, Joshi RS, Beniwal A, Spatz J, Gill S, Chang AC, Choudhary N, Nguyen AT, Sudhir S, Chalif EJ, Chen JS, Chandra A, Haddad AF, Wadhwa H, Shah SS, Choi S, Hayes JL, Wang L, Yagnik G, Costello JF, Diaz A, Heiland DH, Aghi MK. Jain S, et al. Among authors: gill s. J Clin Invest. 2023 Mar 1;133(5):e147087. doi: 10.1172/JCI147087. J Clin Invest. 2023. PMID: 36856115 Free PMC article.
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkilä J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E. Illuzzi G, et al. Among authors: gill sj. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301. Clin Cancer Res. 2022. PMID: 35929986 Free PMC article.
Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial.
Pries-Heje MM, Wiingaard C, Ihlemann N, Gill SU, Bruun NE, Elming H, Povlsen JA, Madsen T, Jensen KT, Fursted K, Schultz M, Østergaard L, Christensen JJ, Christiansen U, Rosenvinge F, Helweg-Larsen J, Fosbøl EL, Køber L, Torp-Pedersen C, Tønder N, Moser C, Iversen K, Bundgaard H. Pries-Heje MM, et al. Among authors: gill su. N Engl J Med. 2022 Feb 10;386(6):601-602. doi: 10.1056/NEJMc2114046. N Engl J Med. 2022. PMID: 35139280 Clinical Trial. No abstract available.
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW. Matthews AH, et al. Among authors: gill si. Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265. Blood Adv. 2022. PMID: 35507945 Free PMC article.
Rapid manufacturing of non-activated potent CAR T cells.
Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA, Reddy S, Bushman FD, Gill SI, O'Doherty U, O'Connor RS, Milone MC. Ghassemi S, et al. Among authors: gill si. Nat Biomed Eng. 2022 Feb;6(2):118-128. doi: 10.1038/s41551-021-00842-6. Epub 2022 Feb 21. Nat Biomed Eng. 2022. PMID: 35190680 Free PMC article.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: gill sc. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
2,457 results